* Beam Therapeutics Inc BEAM.OQ reported a quarterly
adjusted
loss of $1.17 per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-1.22. The mean expectation of
seventeen analysts for the quarter was for a loss of $1.16 per
share. Wall Street expected results to range from $-1.35 to -94
cents per share.
* Revenue fell 17% to $14.27 million from a year ago;
analysts
expected $14.50 million.
* Beam Therapeutics Inc's reported EPS for the quarter was a
loss
of $1.17.
* The company reported a quarterly loss of $96.67 million.
* Beam Therapeutics Inc shares had fallen by 2.3% this
quarter and
lost 12.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 0.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 9
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Beam Therapeutics
Inc is $49.00
This summary was machine generated from LSEG data November 6 at
05:14 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.16 -1.17 Missed
Jun. 30 2024 -1.13 -1.11 Beat
Mar. 31 2024 -1.42 -1.21 Beat
Dec. 31 2023 -1.01 1.73 Beat